The information contained in this section of the site is intended for US health care professionals and specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.
The OCREVUS Co-pay Program for drug or infusion assistance may be used in a community practice, infusion center, or hospital. For drug assistance only, the program may also be used with specialty pharmacies.
Participating practices, institutions or specialty pharmacies must complete a one-time registration so they may process OCREVUS Co-pay Program payments. To register, call (844) MS-COPAY (844-672-6729).
Enrolled patients will receive a welcome letter with one card to cover their drug and infusion costs.*
Fax a copy of the detailed explanation of benefits (EOB)† to (855) MS-COPAY (855-672-6729) or upload it at OCREVUScopay.com
The requirements for reimbursement must include:
If the EOB does not include any of the above items, additional documentation may be required to process the claim
*Multiple payment methods from the OCREVUS Co-pay Program are available. They include the process shown here, as well as reimbursement by check and electronic funds transfer. For more information, please contact your OCREVUS representative.
†EOBs must be submitted within 545 days from the date of service (DOS) for consideration.
OCREVUS is indicated for the treatment of:
OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion
Reduction in Immunoglobulins:
Monitor the level of immunoglobulins at the beginning of treatment. Monitor during and after discontinuation of treatment with OCREVUS, until B-cell repletion, and especially when recurrent serious infections are suspected. Consider discontinuing OCREVUS in patients with serious opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins
An increased risk of malignancy, including breast cancer, may exist with OCREVUS
Most Common Adverse Reactions
RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions. PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.